|
Patent landscape, scope, and claims: |
United States Drug Patent 9,180,194: Scope, Claims, and Landscape Analysis
United States Patent 9,180,194, titled "Methods for treating inflammation," was granted on November 10, 2015, to Adare Pharmaceuticals, Inc. The patent claims methods for treating inflammatory conditions by administering a specific pharmaceutical composition comprising a corticosteroid and a cyclodextrin. The core innovation lies in the use of spray-dried amorphous solid dispersions of budesonide and hydroxypropyl beta-cyclodextrin to enhance solubility and bioavailability. This analysis details the patent’s scope, key claims, and its position within the broader inflammatory disease treatment patent landscape.
What are the Key Inventions Claimed in Patent 9,180,194?
Patent 9,180,194 primarily claims methods of treating inflammatory diseases, specifically focusing on the administration of a novel pharmaceutical formulation designed to improve the delivery and efficacy of corticosteroids. The invention addresses the low aqueous solubility of certain corticosteroids, such as budesonide, which limits their therapeutic potential.
The patent's core invention revolves around spray-dried amorphous solid dispersions. These dispersions incorporate a corticosteroid, such as budesonide, with a cyclodextrin, specifically hydroxypropyl beta-cyclodextrin. This combination, achieved through a spray-drying process, creates an amorphous solid state that significantly enhances the drug's dissolution rate and subsequent absorption.
The claims are directed towards:
- Methods of Treatment: The central claims are for methods of treating inflammatory diseases, including but not limited to inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. These methods involve administering a pharmaceutical composition containing the spray-dried amorphous solid dispersion.
- Pharmaceutical Compositions: While the patent's title emphasizes "methods," the underlying innovation is the composition itself. The claims implicitly or explicitly cover the use of these specific compositions in therapeutic contexts. The composition is defined by the amorphous solid dispersion of budesonide and hydroxypropyl beta-cyclodextrin, prepared by spray drying.
- Specific Conditions: The patent identifies particular inflammatory conditions as targets for its therapeutic methods. This includes Crohn's disease and ulcerative colitis, where enhanced delivery of corticosteroids can be beneficial.
How Broadly Do the Claims of Patent 9,180,194 Extend?
The scope of United States Patent 9,180,194 is defined by its claims, which specify the boundaries of the invention protected. The claims are narrowly focused on the specific method of administration and the nature of the pharmaceutical composition used.
Claim 1, as an independent claim, is central to understanding the patent's breadth. It typically defines a method for treating an inflammatory disease comprising:
- Administering to a subject an effective amount of a pharmaceutical composition.
- This composition comprises a corticosteroid and a cyclodextrin, wherein the corticosteroid and the cyclodextrin are present in an amorphous solid dispersion prepared by spray drying.
- The corticosteroid is specifically identified as budesonide.
- The cyclodextrin is identified as hydroxypropyl beta-cyclodextrin.
Dependent claims then further refine these aspects. For instance, they may specify:
- The inflammatory disease being treated, such as Crohn's disease or ulcerative colitis.
- The physical state of the amorphous solid dispersion, including specific characterization methods like X-ray powder diffraction (XRPD) showing no crystalline budesonide.
- The ratio of budesonide to hydroxypropyl beta-cyclodextrin.
- The particle size distribution of the spray-dried dispersion.
- The route of administration, such as oral administration.
The patent does not claim the corticosteroid or the cyclodextrin in isolation, nor does it claim all methods of treating inflammatory diseases with corticosteroids. Its protection is specifically tied to the use of the spray-dried amorphous solid dispersion of budesonide and hydroxypropyl beta-cyclodextrin for treating inflammatory conditions. This specificity limits the patent's reach to formulations and administration methods that directly employ this particular technological approach.
What is the Status of Patent 9,180,194?
United States Patent 9,180,194 was granted on November 10, 2015. As of the present date, the patent is still within its statutory term. United States utility patents typically have a term of 20 years from the date on which the application for the patent was filed, subject to the payment of maintenance fees.
To determine its current enforceability and expiration date, one would need to:
- Verify Maintenance Fee Payments: The United States Patent and Trademark Office (USPTO) requires periodic maintenance fee payments for patents to remain in force. These are due at 3.5, 7.5, and 11.5 years after the patent grant date. Failure to pay these fees results in the patent expiring prematurely.
- Check for Post-Grant Challenges: The patent could have been subject to post-grant review proceedings, such as Inter Partes Review (IPR) or Post Grant Review (PGR), which could impact its validity and claims. These proceedings, if initiated, could lead to the patent being invalidated in whole or in part, or its claims being amended.
- Examine Any Extensions: In certain cases, patent terms can be extended, for example, through the Patent Term Adjustment (PTA) or Patent Term Extension (PTE) mechanisms, often related to regulatory review periods for drug products.
Assuming all maintenance fees have been paid and no successful challenges have occurred to invalidate the patent or significantly shorten its term, the patent would be expected to remain in force until 20 years from its filing date, potentially with adjustments. The filing date for U.S. Patent Application No. 13/785,072, which matured into Patent 9,180,194, was March 4, 2013 [1]. Therefore, without any specific extensions or challenges, its basic term would extend to March 4, 2033.
What are the Major Challenges or Opportunities Presented by This Patent?
The primary challenges and opportunities associated with Patent 9,180,194 stem from its specific claims and the therapeutic area it addresses.
Opportunities:
- Market Exclusivity: The patent provides Adare Pharmaceuticals, Inc. (or its licensees) with a period of market exclusivity for methods utilizing the claimed spray-dried amorphous solid dispersion technology for treating specific inflammatory diseases. This exclusivity can be leveraged to secure market share and recoup R&D investments.
- Licensing and Partnerships: The patent represents an opportunity for licensing to other pharmaceutical companies seeking to develop or market budesonide-based therapies for inflammatory conditions using this advanced drug delivery system.
- Foundation for New Formulations: The technology disclosed in the patent can serve as a foundation for developing next-generation treatments with improved patient compliance and therapeutic outcomes, potentially expanding the use of budesonide beyond current applications.
- Defense Against Biosimilars/Generics (Indirect): While this patent is method-of-treatment focused and on a specific formulation technology, it can indirectly support differentiation of branded products from generic alternatives that do not employ the spray-dried amorphous solid dispersion, particularly if the patent holder markets a drug product based on this technology.
Challenges:
- Narrow Claim Scope: The patent's claims are specific to the spray-dried amorphous solid dispersion of budesonide and hydroxypropyl beta-cyclodextrin. Competitors could potentially design around this patent by developing alternative formulations or delivery systems for budesonide or other corticosteroids that do not fall under these claims. This might include different amorphous solid dispersion techniques, alternative excipients, or entirely different drug delivery mechanisms.
- Existing Budesonide Formulations: The market already has established budesonide formulations for inflammatory diseases (e.g., oral capsules, inhalers). Patent 9,180,194's impact will depend on the demonstrated advantages of its claimed technology over these existing options in terms of efficacy, safety, and patient adherence.
- Patent Litigation Risk: As with any valuable patent, there is a risk of patent litigation. Competitors may challenge the patent's validity through post-grant review proceedings or claim infringement and seek to invalidate or narrow the patent's scope.
- Regulatory Hurdles: While the patent provides IP protection, any drug product developed based on this technology must still undergo rigorous clinical trials and obtain regulatory approval from bodies like the U.S. Food and Drug Administration (FDA).
- Competition from Other Drug Classes: Inflammatory diseases are treated with a wide array of drugs, including biologics and other small molecules. The success of budesonide-based therapies utilizing this patent technology will also depend on their comparative efficacy and safety profiles against these broader treatment options.
What is the Patent Landscape for Inflammatory Disease Treatments and Drug Delivery Technologies?
The patent landscape for inflammatory disease treatments is vast and highly competitive, characterized by continuous innovation in both novel drug discovery and advanced drug delivery systems. Patent 9,180,194 fits within the latter category, focusing on improving the performance of an existing therapeutic agent.
Key Areas within the Landscape:
-
Therapeutic Agents:
- Small Molecules: Patents cover new chemical entities (NCEs) targeting various inflammatory pathways, such as Janus kinase (JAK) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and sphingosine-1-phosphate (S1P) receptor modulators.
- Biologics: This includes monoclonal antibodies (mAbs) targeting cytokines like TNF-alpha, IL-1, IL-6, IL-12/23, and IL-17. The patent landscape here is particularly dense, with numerous companies holding patents on specific antibody sequences, therapeutic targets, and manufacturing processes.
- Gene and Cell Therapies: Emerging areas with patents covering engineered cells or genetic modifications aimed at modulating immune responses.
-
Drug Delivery Technologies:
- Amorphous Solid Dispersions (ASDs): This is the core technology relevant to Patent 9,180,194. Patents in this space cover various methods of creating ASDs, including spray drying, hot-melt extrusion, and solvent evaporation, as well as novel excipients (polymers, cyclodextrins) used to stabilize the amorphous state. Companies invest heavily in patents related to specific formulations that enhance the solubility and bioavailability of poorly soluble drugs like budesonide.
- Nanoparticle and Microparticle Formulations: Patents exist for encapsulating drugs in liposomes, polymeric nanoparticles, or microparticles for targeted delivery, controlled release, or improved cellular uptake.
- Oral Delivery Systems: Innovations in enteric coatings, extended-release mechanisms, and permeation enhancers designed to improve oral drug absorption and targeting to specific parts of the gastrointestinal tract.
- Topical and Transdermal Delivery: For skin-related inflammatory conditions, patents focus on novel vehicles, penetration enhancers, and reservoir systems for sustained topical or transdermal drug delivery.
- Pulmonary Delivery: For respiratory inflammatory diseases, patents cover advanced inhaler devices and dry powder formulations designed for efficient lung deposition.
-
Combination Therapies:
- Patents may claim the co-administration of different classes of drugs for synergistic effects in managing complex inflammatory conditions.
Patent 9,180,194's Position:
Patent 9,180,194 is situated within the drug delivery technology segment, specifically focusing on amorphous solid dispersions using cyclodextrins for poorly soluble corticosteroids. Its novelty lies in the specific combination of spray drying, budesonide, and hydroxypropyl beta-cyclodextrin for treating inflammatory diseases.
The broader patent landscape highlights the strategic importance of improving drug performance. Companies like Adare Pharmaceuticals, Inc. (now part of Aptar Pharma) focus on developing enabling technologies that can be applied across a portfolio of drugs. These technologies, like ASDs, aim to overcome formulation challenges, thereby extending the lifecycle of existing drugs or enabling the development of new ones. The presence of numerous patents in ASDs indicates a crowded but active field, where specific process parameters, excipient combinations, and target drugs are key differentiators.
Companies operating in this space must navigate a complex web of existing patents to avoid infringement while simultaneously seeking to patent their own innovations in drug formulation and delivery to gain a competitive advantage.
Key Takeaways
- United States Patent 9,180,194 protects methods of treating inflammatory diseases using a spray-dried amorphous solid dispersion of budesonide and hydroxypropyl beta-cyclodextrin.
- The patent's scope is specifically defined by the use of this particular formulation technology, emphasizing enhanced solubility and bioavailability of budesonide.
- The patent was granted on November 10, 2015, and assuming timely maintenance fee payments and no successful challenges, its term is expected to extend to March 4, 2033.
- Opportunities lie in market exclusivity, licensing, and developing advanced formulations. Challenges include narrow claim scope, competition from existing treatments, and potential patent litigation.
- The patent is situated within a broader landscape of inflammatory disease treatments and drug delivery technologies, where amorphous solid dispersions are a key area of innovation.
Frequently Asked Questions
-
What is the primary therapeutic application claimed by U.S. Patent 9,180,194?
The primary therapeutic application claimed is the treatment of inflammatory diseases, specifically mentioning conditions like inflammatory bowel disease, Crohn's disease, and ulcerative colitis.
-
What specific drug and excipient combination is central to the claims of Patent 9,180,194?
The patent centrally claims the use of budesonide as the corticosteroid and hydroxypropyl beta-cyclodextrin as the cyclodextrin, formulated as a spray-dried amorphous solid dispersion.
-
How is the innovation in Patent 9,180,194 distinct from other budesonide treatments?
The innovation is distinct due to its specific focus on a spray-dried amorphous solid dispersion that enhances the solubility and bioavailability of budesonide, rather than claiming budesonide itself or other formulation types.
-
What is the expected expiration date for U.S. Patent 9,180,194?
Assuming all maintenance fees have been paid and no term extensions or challenges have occurred, the patent is expected to expire on March 4, 2033, which is 20 years from its U.S. filing date.
-
Could a competitor develop a generic version of a drug product utilizing the technology claimed in Patent 9,180,194 before its expiration?
A competitor could not legally market a drug product that directly utilizes the method of treatment or the specific formulation claimed in Patent 9,180,194 before its expiration without a license. However, they might develop alternative budesonide formulations or treatments that do not infringe on the patent's specific claims.
Citations
[1] United States Patent 9,180,194. (2015, November 10). Methods for treating inflammation. Adare Pharmaceuticals, Inc.
More… ↓
⤷ Start Trial
|
